# PRKCSH

## Overview
The PRKCSH gene encodes the protein kinase C substrate 80K-H, also known as hepatocystin, which serves as the beta-subunit of glucosidase II, a critical enzyme in the endoplasmic reticulum (ER) involved in glycoprotein processing and quality control. This protein plays a pivotal role in the N-glycan processing pathway, ensuring proper folding and maturation of glycoproteins by trimming glucose residues. The protein kinase C substrate 80K-H is characterized by several functional domains, including a carbohydrate-binding domain, EF-hand domains for calcium binding, and a C-terminal HDEL sequence for ER retention, which are essential for its localization and function within the cell (DRENTH2005Polycystic; Cressey2024Navigating). Beyond its role in glycoprotein processing, PRKCSH is involved in various cellular interactions, influencing processes such as calcium signaling and tumor cell survival, and is implicated in conditions like autosomal dominant polycystic liver disease and cancer (Lei2022Potential; Shin2019PRKCSH).

## Structure
The PRKCSH gene encodes the beta-subunit of glucosidase II, a protein involved in the folding and quality control of glycoproteins within the endoplasmic reticulum. The primary structure of this protein consists of a sequence of amino acids that form specific domains, including a carbohydrate-binding domain, which is crucial for its function in glycoprotein processing. 

In terms of secondary structure, the protein may contain alpha-helices and beta-sheets, which contribute to its stability and functional conformation. The tertiary structure of PRKCSH involves the three-dimensional folding of these secondary elements, allowing the protein to achieve its functional form necessary for interaction with substrates and other cellular components. 

The quaternary structure of PRKCSH refers to its interaction with other subunits, forming a functional glucosidase II enzyme complex. This interaction is essential for its role in the endoplasmic reticulum. Post-translational modifications, such as phosphorylation, can occur, potentially influencing the protein's activity and interactions. These structural features collectively enable PRKCSH to perform its role in protein quality control effectively.

## Function
The PRKCSH gene encodes hepatocystin, the beta-subunit of glucosidase II, which is crucial for the N-glycan processing pathway within the endoplasmic reticulum (ER) of healthy human cells. This protein plays a significant role in the folding and quality control of newly synthesized glycoproteins by trimming glucose residues, a process essential for proper protein maturation and function (DRENTH2005Polycystic; Cressey2024Navigating). Hepatocystin is involved in the ER's quality control system, ensuring that only properly folded proteins are released, while misfolded proteins are retained for further processing or degradation (Cressey2024Navigating).

Hepatocystin contains several domains, including a signal peptide for ER translocation, EF-hand domains for calcium binding, and a C-terminal HDEL sequence for ER retention, which are critical for its function and localization within the cell (DRENTH2005Polycystic). The protein also interacts with the glucosidase II alpha-subunit, facilitating its proper localization and function within the ER (Shin2019PRKCSH). In addition to its role in glycoprotein processing, hepatocystin may regulate calcium-dependent processes, such as the epithelial calcium channel TRPV5, highlighting its broader impact on cellular homeostasis (Cressey2024Navigating).

## Clinical Significance
Mutations in the PRKCSH gene are primarily associated with isolated autosomal dominant polycystic liver disease (ADPLD). These mutations often lead to premature chain termination, resulting in the loss of the highly conserved terminal four amino acids, His-Asp-Glu-Leu (HDEL), which are crucial for endoplasmic reticulum (ER) retention. This loss likely causes the protein to enter the secretory pathway and be trafficked out of the cell, contributing to the development of liver cysts (Li2003Mutations). The mutations in PRKCSH are considered loss-of-function changes, although dominant negative or gain-of-function effects cannot be excluded (Li2003Mutations).

PRKCSH is also implicated in cancer. Altered expression of PRKCSH is linked to various cancers, including lung adenocarcinoma, bladder urothelial carcinoma, and breast invasive carcinoma. High PRKCSH expression is associated with poor prognosis in several cancers, suggesting its role as an oncogene (Lei2022Potential). PRKCSH expression correlates with immune cell infiltration in the tumor microenvironment, indicating its potential role in immune evasion by tumors (Wang2024PRKCSH). Additionally, PRKCSH is involved in the unfolded protein response and activates the IRE1a signaling pathway, which is linked to tumor cell adaptation and tumorigenesis (Cressey2024Navigating).

## Interactions
PRKCSH, also known as protein kinase C substrate 80K-H, is involved in various protein interactions that play significant roles in cellular processes. It is a regulatory subunit of the glucosidase II enzyme, interacting with the catalytic alpha subunit (GluIIa) to facilitate N-linked glycoprotein processing in the endoplasmic reticulum (ER) (Cressey2024Navigating). PRKCSH interacts with IRE1α, a key player in the unfolded protein response (UPR), promoting its autophosphorylation and oligomerization under ER stress conditions. This interaction enhances the IRE1α signaling pathway, which is crucial for tumor cell adaptation and survival (Shin2019PRKCSH).

PRKCSH also interacts with the insulin-like growth factor 1 receptor (IGF1R), extending its half-life and enhancing its activation. This interaction contributes to resistance against the tumor necrosis factor superfamily (TNFSF) in lung cancer cells by inhibiting caspase-8 and caspase-9 activation, thereby promoting cell survival (Shin2024PRKCSH). Additionally, PRKCSH competes with HERPUD1 to regulate IGF1R stability, with its MRH domain being critical for this interaction (Shin2024PRKCSH).

PRKCSH's interactions extend to other proteins such as inositol 1,4,5-trisphosphate receptors (IP3Rs) and the epithelial calcium channel TRPV5, influencing calcium release and signaling pathways in various cell types (Cressey2024Navigating). These interactions highlight PRKCSH's multifaceted role in cellular homeostasis and cancer progression.


## References


[1. (Cressey2024Navigating) Ratchada Cressey, Moe Thi Thi Han, Worapong Khaodee, Guo Xiyuan, and Yuan Qing. Navigating prkcsh’s impact on cancer: from n-linked glycosylation to death pathway and anti-tumor immunity. Frontiers in Oncology, March 2024. URL: http://dx.doi.org/10.3389/fonc.2024.1378694, doi:10.3389/fonc.2024.1378694. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2024.1378694)

[2. (Shin2024PRKCSH) Gu-Choul Shin, Hyeong Min Lee, Nayeon Kim, Sang-Uk Seo, Kwang Pyo Kim, and Kyun-Hwan Kim. Prkcsh contributes to tnfsf resistance by extending igf1r half-life and activation in lung cancer. Experimental &amp; Molecular Medicine, 56(1):192–209, January 2024. URL: http://dx.doi.org/10.1038/s12276-023-01147-1, doi:10.1038/s12276-023-01147-1. This article has 2 citations.](https://doi.org/10.1038/s12276-023-01147-1)

[3. (Shin2019PRKCSH) Gu-Choul Shin, Sung Ung Moon, Hong Seok Kang, Hyo-Sun Choi, Hee Dong Han, and Kyun-Hwan Kim. Prkcsh contributes to tumorigenesis by selective boosting of ire1 signaling pathway. Nature Communications, July 2019. URL: http://dx.doi.org/10.1038/s41467-019-11019-w, doi:10.1038/s41467-019-11019-w. This article has 30 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-019-11019-w)

[4. (DRENTH2005Polycystic) J DRENTH, J MARTINA, R KERKHOF, J BONIFACINO, and J JANSEN. Polycystic liver disease is a disorder of cotranslational protein processing. Trends in Molecular Medicine, 11(1):37–42, January 2005. URL: http://dx.doi.org/10.1016/j.molmed.2004.11.004, doi:10.1016/j.molmed.2004.11.004. This article has 70 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.molmed.2004.11.004)

[5. (Li2003Mutations) Airong Li, Sonia Davila, Laszlo Furu, Qi Qian, Xin Tian, Patrick S. Kamath, Bernard F. King, Vicente E. Torres, and Stefan Somlo. Mutations in prkcsh cause isolated autosomal dominant polycystic liver disease. The American Journal of Human Genetics, 72(3):691–703, March 2003. URL: http://dx.doi.org/10.1086/368295, doi:10.1086/368295. This article has 161 citations.](https://doi.org/10.1086/368295)

[6. (Wang2024PRKCSH) Qiankun Wang, Xiong Wang, Jiaoyuan Li, Tongxin Yin, Yi Wang, and Liming Cheng. Prkcsh serves as a potential immunological and prognostic biomarker in pan-cancer. Scientific Reports, January 2024. URL: http://dx.doi.org/10.1038/s41598-024-52153-w, doi:10.1038/s41598-024-52153-w. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-024-52153-w)

[7. (Lei2022Potential) Ridan Lei, Meiling Zhou, Shusheng Zhang, Jinhua Luo, Can Qu, Yin Wang, Peiyu Guo, and Ruixue Huang. Potential role of prkcsh in lung cancer: bioinformatics analysis and a case study of nano zno. Nanoscale, 14(12):4495–4510, 2022. URL: http://dx.doi.org/10.1039/d1nr08133k, doi:10.1039/d1nr08133k. This article has 9 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1039/d1nr08133k)